Muscle Exosomes

Overview

Parent Cell: Akira Skeletal Muscle Stem Cells (MuSCs) differentiated from UCT-WJ-MSCs | Muscle-regenerative and anti-atrophic growth factors and miRNAs for muscle repair and regeneration

What Are Exosomes?

Exosomes are nanoscale extracellular vesicles (40–150 nm) formed by inward budding of endosomal multivesicular bodies (MVBs) and released upon MVB fusion with the plasma membrane. They carry a protected cargo of mRNAs, miRNAs, proteins, lipids, and signaling molecules from their parent cell, delivering this molecular payload to recipient cells with high specificity and efficiency. Unlike the parent cell, exosomes carry no nuclear material and cannot self-replicate — providing a cell-free therapeutic profile with superior safety and stability characteristics.

The Akira Muscle Exosome Matrix is derived from skeletal muscle stem cells (MuSCs, also known as satellite cells) produced by directed differentiation of UCT-WJ-MSCs under myogenic induction conditions. These cells express the canonical satellite cell marker Pax7 and the myogenic regulatory factors MyoD and Myogenin, confirming their skeletal muscle progenitor identity. The resulting exosome preparation is enriched with the molecular signals of muscle regeneration, hypertrophy, and anti-atrophy.

Muscle-derived exosomes are an emerging area of research interest due to their role as exercise-induced myokine carriers and their potential in treating muscle wasting conditions (sarcopenia, cachexia, muscular dystrophy). The miRNA cargo of this preparation — miR-206, miR-1, miR-133a/b — collectively regulate satellite cell activation, myoblast proliferation, muscle fiber hypertrophy, and anti-fibrotic remodeling. Follistatin in the secretome is a potent myostatin antagonist, providing direct anti-atrophy signaling.^[1]

Mechanism of Action

Satellite Cell Activation & Myogenesis: HGF activates quiescent satellite cells through the c-Met receptor, initiating the myogenic program. miR-206 — the defining muscle miRNA — promotes MyoD expression and myoblast differentiation while suppressing PAX7 to drive terminal differentiation. miR-1 reinforces myogenic commitment by suppressing HDAC4. FGF-2 drives satellite cell proliferation to expand the myoblast pool prior to fusion and hypertrophic remodeling.

Muscle Fiber Hypertrophy & IGF-1 Signaling: IGF-1 activates PI3K/Akt/mTOR in myofibers, the primary pathway driving protein synthesis and muscle hypertrophy. miR-486 suppresses PTEN, amplifying PI3K/Akt signaling. This combination of direct IGF-1 cargo and PTEN-suppressing miRNA creates a potent pro-hypertrophic environment in recipient muscle tissue, relevant to sarcopenia, atrophy, and muscle-wasting research contexts.

Myostatin Antagonism & Anti-Atrophy: Follistatin is the primary endogenous antagonist of myostatin (GDF-8), the key negative regulator of muscle mass. The Muscle Exosome secretome delivers follistatin at concentrations sufficient to substantially reduce myostatin signaling in recipient tissues. miR-133a/b additionally suppress myostatin-associated downstream targets. This dual anti-myostatin mechanism is directly relevant to cachexia, sarcopenia, and muscular dystrophy research.^[2]

Muscle Fibrosis Reduction: TGF-β signaling in injured muscle drives fibro/adipogenic progenitor (FAP) activation and replacement of functional muscle with fibrotic connective tissue. miR-133a suppresses connective tissue growth factor (CTGF) and TGF-β pathway components in FAPs, reducing fibrotic replacement of damaged muscle. This is particularly relevant in chronic muscle disease (Duchenne MD) and recurrent injury contexts.

Key Molecular Cargo

Therapeutic Applications

???

Clinical & Preclinical Evidence

???